Show Summary Details
Page of

Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial 

Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial
Chapter:
Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial
Author(s):

Allison Arch

and David Y. Hwang

DOI:
10.1093/med/9780199377527.003.0036
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 September 2019

This chapter provides a summary of a landmark study in vascular neurology. Is intra-arterial thrombolysis plus intravenous heparin effective and safe in patients with acute ischemic stroke caused by middle cerebral artery occlusion, compared to intravenous heparin alone? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The study was the first randomized trial to demonstrate clinical efficacy of intra-arterial thrombolysis in patients with acute stroke of less than 6 hours’ duration caused by middle cerebral artery occlusion. The chapter briefly reviews other relevant studies and information and concludes with the main study’s implications.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.